Healthcare Web Wire

Tag: Insulin Pump Market

MiniMed vs Tandem: 40% Dominance Meets the Fastest-Growing Insulin Pump Segment
The MiniMed segment captured a dominant 40% insulin pump market share in 2025, setting a strong benchmark.

Download Free Sample: https://www.towardshealthcare.com/download-sample/5025

This leadership is not accidental.
It reflects how technology is reshaping patient behavior and clinical outcomes.

MiniMed pumps operate on automated insulin delivery systems.
They adjust insulin levels every 5 minutes, reducing manual intervention.

This is what makes them stand out:
- Continuous glucose monitoring without finger pricks
- Real-time insulin correction, 24×7
- Reduced risk of needlestick injuries
- Data-driven support for clinical decision-making
Patients no longer depend on periodic checks.
Instead, they live with a system that thinks and responds in real time.

The Rise of Intelligence in Diabetes Care

Insulin pumps are no longer just devices.
They are becoming intelligent companions in chronic disease management.

The shift is visible in how systems now:
- Learn from patient data
- Predict glucose fluctuations
- Adjust insulin delivery proactively
This creates a feedback loop between patient, device, and healthcare provider.

The result?
Better control, fewer complications, and improved quality of life.

Tandem Segment: Small Size, Big Momentum

While MiniMed leads, the Tandem segment is quietly building momentum.
Holding around 25% share, it is expected to grow at the fastest pace.

The growth story here is driven by usability and personalization.

Tandem pumps are designed to be up to 38% smaller.
That matters more than it sounds — smaller devices improve daily comfort and adoption.

But size is only part of the equation.

Key growth drivers include:
- Smartphone-based control for real-time adjustments
- Closed-loop systems that automate insulin delivery
- AI-based sensors improving accuracy and response
- Reduced dependency on manual intervention
This combination of convenience and intelligence is attracting a new generation of users.

What the Numbers Are Really Saying

Market share alone does not tell the full story.
The underlying trend is a shift toward automation and personalization.

Let’s break it down statistically:
- 40% — MiniMed dominates with advanced automation
- 25% — Tandem gains traction with user-centric innovation
- High CAGR expected in smart, connected pump systems
- Increasing adoption due to reduced infection risks and improved safety
These numbers point to one clear direction —
patients prefer systems that reduce effort and increase control.

From Devices to Daily Companions

The insulin pump is no longer just a medical tool.
It is becoming part of a patient’s everyday life.

Patients today look for:
- Comfort in wearing the device
- Confidence in automated decisions
- Control through digital interfaces
This is why smartphone integration and AI are no longer optional features.
They are becoming standard expectations.

The Bigger Shift: Human-Centered Innovation

What stands out in 2025 is not just competition between products.
It is a deeper shift toward human-centered healthcare design.

Companies are no longer asking, “How do we improve the device?”
They are asking, “How do we improve the patient’s life?”

This mindset is driving:
- Smaller, smarter, and safer devices
- Real-time data accessibility
- Reduced clinical burden on healthcare systems
Access our exclusive, data-rich dashboard dedicated to the medical devices industry – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

Checkout the Market Report Now at: https://www.towardshealthcare.com/checkout/5025

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region – +44 778 256 0738

North America Region – +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium
March 17, 2026
Insulin Pump Market Size, Shares, Key Players and Industry Reports 2034

The global Insulin Pump Market is projected to grow from USD 6.87 billion in 2024 to USD 17.25 billion by 2034, expanding at a CAGR of 9.65%, driven by rising diabetes prevalence and continuous innovation in AI-enabled and CGM-integrated insulin pumps.

Download Free Sample of Insulin Pump Market Now and Get the Complete Report Easily at: https://www.towardshealthcare.com/download-sample/5025

Market Size

Market Value Growth:

2024: USD 6.87 billion

2034: USD 17.25 billion

CAGR: 9.65% (2025–2034)

Strong growth led by AI integration, wearable technologies, and automation of insulin delivery.

Volume Expansion:

Over 12 million active insulin pump users globally in 2024.

Expected to surpass 25 million by 2034, with North America and Europe accounting for over 60% of users.

Revenue Distribution by Region (2024):

North America: ~42%

Europe: ~28%

Asia Pacific: ~22%

Rest of World (Latin America + MEA): ~8%

Forecast Drivers:

Increasing diabetic population—projected to reach 783 million globally by 2045 (IDF).

Higher adoption of closed-loop systems and tubeless pumps.

Profit Margins:

Insulin pump manufacturers enjoy EBITDA margins of 25–30%, especially those offering CGM-integrated smart pumps.

End-Use Contribution:

Hospitals: ~55% of revenue (2024)

Homecare: fastest growth at CAGR >10% due to remote management and geriatric population.

Technological Investment:

Over USD 1.2 billion invested globally (2024–2025) in R&D for AI, CGM, and wireless insulin systems.

Long-Term Growth Catalyst:

Digital health ecosystem integration (AI + mobile app + CGM sensors).

Government support for diabetic care reimbursement (Medicare, NHS, Health Canada).

Market Trends

Integration of CGM and Insulin Pumps:

Tandem and Medtronic integrating continuous glucose monitoring for automated insulin adjustment.

In August 2024, Medtronic partnered with Abbott to integrate FreeStyle Libre technology with its smart insulin systems.

Rise of Patch Pumps:

Compact, tubeless patch pumps gaining preference for convenience and reduced infection risk.

Expected to grow fastest through 2034.

AI-Driven Automation:

AI enabling predictive dose delivery and error reduction, supporting closed-loop insulin systems.

Miniaturization & Portability:

Tandem’s Tandem Mobi, world’s smallest automated insulin pump, launched Feb 2024.

Regulatory Support & Reimbursement Policies:

Medicare and Health Canada support 80%–100% cost reimbursement for qualified devices.

Collaborative Ecosystems:

Tandem’s long-term R&D partnership with University of Virginia (2025) accelerates automated insulin systems.

Shift Toward Homecare Usage:

Increasing geriatric population driving self-administration and remote monitoring.

Personalized Insulin Delivery:

AI algorithms enable adaptive insulin dosing based on patient’s daily glucose trends.

Hybrid Closed-Loop System Approvals:

Health Canada approved Omnipod 5 (April 2024), integrating Dexcom G6 CGM sensor.

Expansion in Emerging Economies:

India and China showing rapid insulin pump adoption due to rising diabetes prevalence and government screening initiatives.

10 Deep AI Impacts / Roles in Insulin Pump Market

Automated Insulin Delivery:

AI regulates insulin release based on CGM data, maintaining glucose levels automatically without manual intervention.

Predictive Dose Adjustment:

Algorithms forecast glucose spikes, adjusting insulin proactively—reducing hypo- and hyperglycemia risks.

Personalized Therapy:

AI tailors insulin doses according to patient’s food intake, activity level, and body metabolism patterns.

Continuous Learning Models:

Machine learning improves accuracy over time by analyzing patient-specific glucose variations.

Integration with Wearables:

Smart AI-enabled devices provide 24×7 health tracking via Bluetooth or smartphone apps.

Remote Monitoring & Telehealth:

AI analytics allow doctors to review data remotely and adjust therapies in real time.

Error Reduction in Dosing:

AI minimizes human error by eliminating manual calculations of insulin bolus doses.

Early Detection of Complications:

AI identifies abnormal glucose fluctuations, predicting diabetic ketoacidosis (DKA) risk early.

Enhanced User Experience:

Voice-assisted or app-based AI interfaces help elderly patients manage pumps easily.

Clinical Research Acceleration:

AI-driven data from millions of users assists in faster clinical trials and new product validation for insulin technologies.

Regional Insights

1. North America (Dominant Region – 42% Market Share in 2024)

Key Drivers:

High obesity and diabetes prevalence (1 in 10 Americans diabetic).

Strong regulatory approval system (FDA).

Major players like Medtronic, Tandem, and Insulet based here.

Reimbursement Advantage:

Medicare Parts A & B cover up to 80% of pump costs.

Adoption Rate:

Over 500,000 Americans on insulin pump therapy.

Growth Catalyst:

Technological integration and automation fueling rapid device replacement cycles.

2. Europe (Second-Largest Region – 28% Market Share)

Drivers:

Aging population and rising diabetes prevalence.

EU “Blueprint for Action on Diabetes 2030” promoting insulin pump adoption.

Key Countries: Germany, U.K., France, Italy, Spain.

Technology Adoption:

Strong preference for MiniMed and Accu-Chek due to CE-certified reliability.

3. Asia Pacific (Fastest-Growing Region – CAGR >10%)

High Disease Burden:

India and China together account for over 230 million diabetics.

Market Trends:

Shift to proactive diabetes management through portable pumps.

Healthcare Transformation:

Urbanization, awareness campaigns, and telemedicine adoption.

4. Latin America & MEA (Emerging Regions)

Latin America: Brazil and Mexico driving growth through public diabetes programs.

MEA: Adoption still limited but improving due to growing healthcare infrastructure in the UAE and Saudi Arabia.

Market Dynamics

Drivers:

Rising Diabetes Prevalence: 783 million projected cases by 2045 (IDF).

Technological Advancement: AI-based closed-loop systems improving therapy precision.

Favorable Reimbursement: Medicare and EU health initiatives boost affordability.

Miniaturization and Comfort: Lightweight, wireless designs improving user compliance.

Restraints:

High Device Cost: Average pump system USD 4,000–6,000 limits adoption in low-income regions.

Training & Skill Requirements: Need for professional guidance in usage.

Hospital Contraindications: Not suitable for unconscious or critical patients.

Opportunities:

Emerging Markets: India and China’s massive diabetic base.

AI and IoT Integration: Data-driven smart diabetes management.

Portable Homecare Devices: Catering to elderly population.

Leaders You Should Know in Insulin Pump Market

Medtronic Plc

Product: MiniMed Series

Overview: Global leader in insulin automation.

Strength: Advanced hybrid closed-loop technology; strong distribution in North America & Europe.

Insulet Corporation

Product: Omnipod 5

Overview: Pioneer of tubeless insulin pumps.

Strength: Compact wireless design, integrated CGM with Dexcom sensors.

Tandem Diabetes Care, Inc.

Product: Tandem Mobi

Overview: Specializes in small automated insulin delivery systems.

Strength: Smartphone-controlled AI insulin pump.

F. Hoffmann-La Roche AG (Accu-Chek)

Product: Accu-Chek Combo

Strength: Strong presence in European healthcare systems.

Ypsomed AG

Product: MyLife Omnipod

Strength: Swiss precision engineering, modular pump systems.

Terumo Corporation

Overview: Focused on infusion technology.

Strength: Expertise in precision needles and tubing.

MicroPort Scientific

Overview: China-based firm in medtech solutions.

Strength: R&D in digital insulin pumps for Asia-Pacific.

Debiotech S.A.

Overview: Swiss company developing microfluidic insulin systems.

Strength: Advanced microneedle technology.

Eoflow Co. Ltd.

Product: EOPatch

Strength: Wireless patch pump technology gaining global traction.

Cequr SA

Product: PaQ Insulin Delivery

Strength: Focus on wearable, discrete insulin devices.

Latest Announcement

Tandem Diabetes Care (Jan 2025):
Collaboration with University of Virginia for research in fully automated closed-loop insulin systems.

Medtronic & Abbott (Aug 2024):
Strategic alliance to integrate FreeStyle Libre with Medtronic insulin delivery systems.

Novo Nordisk (Mar 2024):
Acquired Cardior Pharmaceuticals (EUR 1.025 billion) to expand cardiovascular and diabetic disease synergy.

Recent Developments

Health Canada Approval (Apr 2024):
Approved Omnipod 5, integrated with Dexcom G6, to launch in mid-2025.

Tandem Mobi Launch (Feb 2024):
World’s smallest automated pump predicting and preventing hypo/hyperglycemia.

Medtronic Financial Update (2024):
Reported USD 32.4 billion annual revenue, up 3.6% YoY—diabetes care segment growing fastest.

AI Integration R&D:
Companies investing heavily in algorithmic dosing systems for precision insulin control.

Segments Covered

1. By Type

1.1. Tethered Pumps (Dominant Segment, 2024)

Overview:
Tethered pumps are traditional insulin pumps attached to the body via a thin plastic tube (infusion set) that delivers insulin from the pump to a cannula inserted under the skin.

Reasons for Dominance:

Affordability: These pumps are cost-effective compared to newer patch or tubeless models.

Display Interface: They feature LCD screens or smartphone-linked displays that allow real-time monitoring of insulin levels.

Custom Dosing: Users can manually program basal and bolus insulin rates depending on their needs.

Reliability: Proven accuracy and fewer insulin delivery errors compared to early-generation patch pumps.

Technological Integration:

Integration with Continuous Glucose Monitoring (CGM) systems to automate dose adjustments.

Example: Medtronic’s MiniMed 780G—a tethered hybrid closed-loop pump that automatically corrects glucose every 5 minutes.

Growth Prospects:

Expected steady growth due to advanced hybrid-loop designs and increased use in hospital settings where physician supervision is preferred.

1.2. Patch Pumps (Fastest-Growing Segment, 2025–2034)

Overview:
Patch pumps are tubeless, adhesive-based devices worn directly on the skin. They deliver insulin through a short cannula inserted under the skin.

Key Features:

Wireless Operation: Controlled via a remote or mobile app (no tubing).

Discreet and Lightweight: Designed for mobility, especially for children and working adults.

Reduced Risk of Infection: Eliminates tubing-related contamination or disconnection.

Growth Drivers:

Ease of Use: Especially suitable for elderly and pediatric patients.

Integration with AI: Many patch pumps feature predictive algorithms to prevent hypo/hyperglycemia.

Example: Insulet’s Omnipod 5, approved in 2024, offers wireless insulin delivery integrated with Dexcom G6 CGM sensors.

Market Potential:

Expected CAGR >12% (2025–2034).

Rising acceptance in homecare and outpatient diabetes management.

2. By Product

2.1. MiniMed (Largest Market Share, 2024)

Manufacturer: Medtronic Plc

Overview:
MiniMed insulin pumps dominate the market due to their AI-powered automation and strong brand credibility.

Advantages:

Delivers continuous basal insulin and correction boluses automatically.

Integrated with Guardian Sensor 3 CGM system.

Operates 24×7 without fingerpricks, reducing patient burden.

Adoption:

Popular in North America and Europe; used in both Type 1 and Type 2 diabetes.

Market Strength:

Long-standing clinical validation, global distribution, and Medicare reimbursement coverage.

2.2. Tandem (Fastest-Growing Product Segment)

Manufacturer: Tandem Diabetes Care, Inc.

Overview:
Specializes in miniaturized, app-controlled insulin pumps.

Product Highlight: Tandem Mobi – World’s smallest automated insulin delivery system (launched Feb 2024).

Key Features:

Controlled via smartphone (iOS and Android).

Watertight aluminum casing and portable design.

Uses AI algorithms to predict and prevent glycemic events.

Growth Outlook:

Partnership with University of Virginia (2025) to develop fully automated closed-loop systems.

CAGR expected to exceed 13% (2025–2034).

2.3. Accu-Chek, Omnipod, MyLife, Others

Accu-Chek (Roche):

Reliable wired pumps with integrated glucose meters.

Popular in European countries due to established hospital networks.

Omnipod (Insulet):

Tubeless, waterproof patch pumps gaining traction in homecare settings.

MyLife (Ypsomed):

Modular insulin system compatible with multiple infusion sets and cartridges.

3. By Accessories

3.1. Insulin Set Insertion Devices (Leading in 2024)

Function:
Enable precise, consistent placement of cannulas under the skin for insulin delivery.

Advantages:

Simplifies insertion, reducing pain and user error.

Minimizes infection risk through sterile, single-use design.

Enhances consistent insulin absorption.

Market Insights:

Accounts for over 45% of accessory revenue (2024).

Commonly used in both hospital and homecare environments.

Future Outlook:

R&D towards automated insertion devices with disposable integrated sensors.

3.2. Insulin Reservoirs or Cartridges (Fastest-Growing Accessory Segment)

Function:
Store and deliver insulin within the pump; prefilled cartridges are convenient and reduce waste.

Trends:

Lightweight, leak-proof polymer materials enhancing portability.

Integration of safety-lock mechanisms to prevent accidental overdelivery.

Drivers:

Growing patient preference for replaceable cartridges over refillable reservoirs.

Innovation Example:

Medtronic’s Quick-set infusion reservoirs designed for easy attachment and detachment.

4. By Disease Indication

4.1. Type 1 Diabetes (Dominant Segment)

Nature: Autoimmune disorder where the pancreas produces little or no insulin.

Market Share:

Accounts for ~65% of insulin pump users globally (2024).

Reasons for Dominance:

Insulin therapy is a lifelong requirement.

Improved quality of life and glucose control with pump usage.

Technological Impact:

AI-controlled closed-loop systems mimic pancreatic function, reducing glycemic variability.

Integration with smartphone apps allows remote parental monitoring in pediatric cases.

Example:

Medtronic’s MiniMed 780G—FDA approved for patients aged 7+ years with Type 1 diabetes.

4.2. Type 2 Diabetes (Fastest-Growing Segment)

Overview:
Type 2 diabetes patients are increasingly adopting insulin pumps due to uncontrolled glucose levels and insulin resistance.

Growth Factors:

Rising obesity and sedentary lifestyles.

Growing acceptance among healthcare providers for pump therapy in complex cases.

Technology Influence:

Use of automated insulin delivery (AID) systems enhances glycemic control without manual intervention.

Recent Finding:

AI-based systems improved blood glucose control by 25% among Type 2 users in clinical studies.

Market Forecast:

Expected CAGR: 10.5% (2025–2034).

5. By End-Use

5.1. Hospitals & Clinics (Dominant in 2024)

Overview:
Primary site for insulin pump administration, patient training, and clinical supervision.

Key Growth Drivers:

Availability of skilled healthcare professionals and diabetes educators.

Access to advanced medical technologies for continuous glucose monitoring and automated insulin delivery.

Increasing hospitalizations due to diabetes-related complications (e.g., DKA, hyperglycemia).

Adoption in Inpatient Care:

Used for short-term management in surgical or intensive care patients under supervision.

Challenges:

Contraindications include impaired consciousness, psychiatric illness, or lack of trained staff.

5.2. Homecare (Fastest-Growing End-Use Segment)

Overview:
Driven by the rising geriatric population and shift toward self-care.

Market Drivers:

Portable, user-friendly, and tubeless insulin pumps suited for home use.

Integration with mobile apps allows remote monitoring by healthcare providers.

Reimbursement policies cover home-based devices (e.g., Medicare in the U.S.).

Example:

Insulet’s Omnipod 5 allows insulin adjustment via mobile devices, ideal for remote usage.

Outlook:

Expected CAGR: >11% (2025–2034), fastest among end-use categories.

Supported by AI-driven glucose tracking and real-time alerts.

6. Additional Subsegment Insights

Battery Accessories:

Rechargeable or disposable batteries powering pump operation.

Trend toward USB-C rechargeable units for sustainability.

Laboratory Use (Emerging Niche):

Used in clinical trials for insulin delivery efficiency testing and algorithm calibration.

Accounts for small market share (3%) but vital for R&D activities.

Top 5 FAQs

1. What is the projected market size of the insulin pump market by 2034?
The global insulin pump market is expected to reach USD 17.25 billion by 2034, from USD 6.87 billion in 2024, at a CAGR of 9.65%.

2. Which region leads the insulin pump market?
North America dominates the market, supported by strong reimbursement systems and high diabetes prevalence.

3. Which product segment holds the largest share?
MiniMed (Medtronic) segment leads due to advanced automation and continuous insulin delivery systems.

4. What are the key factors driving the market growth?
Rising global diabetes prevalence, AI integration, portable device demand, and supportive reimbursement policies.

5. Which company has the fastest-growing product innovation?
Tandem Diabetes Care with its AI-powered Tandem Mobi insulin pump, launched in 2024, shows the highest growth trajectory.

Access our exclusive, data-rich dashboard dedicated to the medical devices sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

Checkout Insulin Pump Market Report Now at: https://www.towardshealthcare.com/checkout/5025

Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform

Europe Region – +44 778 256 0738

North America Region – +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

November 10, 2025
Insulin Pump Market Poised for Striking Growth of USD 15.28 Billion by 2032

In the dynamic realm of diabetes care, the insulin pump market emerges as a transformative force, projected to reach a substantial valuation of US$ 15.28 billion by the conclusion of 2032. This impressive journey is underlined by a robust Compound Annual Growth Rate (CAGR) of 9.65% over the forecast period. The market’s ascendancy is driven by the unwavering commitment of industry players, focusing on the introduction of technologically advanced Continuous Glucose Monitoring (CGM) systems and insulin pumps.

Riding the Wave: Unpacking the Drivers of Market Expansion

Technological Advancements: Catalyst for Transformation

At the core of the market’s growth is the relentless pursuit of technological advancements. The continual innovation in CGM systems and insulin pump market revolutionizes diabetes management, providing patients with more efficient and user-friendly solutions. As industry players prioritize technological breakthroughs, the market gains momentum and becomes a cornerstone in diabetes care.

Industry Players’ Focus: Driving Innovation

The impetus for market growth is propelled by the concerted efforts of industry players dedicated to advancing diabetes care. The strategic focus on launching state-of-the-art CGM systems and insulin pump market amplifies traction. This commitment not only meets the evolving needs of patients but also positions the market as a hub for innovation within the healthcare landscape.

Insulin pump market can make it easier for diabetics to conveniently control their blood sugar levels.

An insulin pump market delivers consistent insulin doses all day long to the body. This pump is handy and easy to use, and it is worn externally on a belt, in a pocket, or a pouch. A tiny plastic tube and a needle with a very small diameter connect to the insulin pump. The plastic tube containing the needle is inserted under your skin, then the needle is removed. The plastic tube will remain implanted and connected to the insulin pump market for several days.

The device can be set to give you insulin depending on your needs and continuously pumps insulin into your body through the tube. At mealtimes, you can administer insulin dosages to yourself using the pump.

In the USA, diabetes mellitus affects an estimated 1 in 10 persons, and both the incidence and obesity rates are on the rise. Diabetes patients are more likely to experience consequences like hospitalizations and hypo-or hyperglycemia, metabolic co-morbidities, or, as we’ve lately observed, more severe sickness from viruses like SARS-CoV-2.

Glycemic targets recommended by the American Diabetes Association during hospitalization aid in enhancing clinical outcomes and minimizing complications. Therefore, it is crucial for the health of individuals with diabetes to maintain euglycemia in both the outpatient and the inpatient setting.

According to the IDF (International Diabetes Foundation), Atlas, 6.7 million people will die from diabetes worldwide in 2021, and by 2045, the disease will affect 51% more individuals.

In the last ten years, the global Insulin pump market share has advanced significantly and will anticipate that trend to continue exponentially. Even though the number of individuals with diabetes is still growing, the global insulin market has already seen spectacular development.

An insulin pump market might be a pleasant reprieve for diabetics who are sick of taking needles. Insulin is necessary for everyone with type 1 diabetes and many people with type 2 diabetes to manage their disease. Using an insulin pump or injecting with a syringe or pen are the two major ways to administer insulin. Insulin pens or several daily injections with syringes are unnecessary with insulin pumps.

However, it can be difficult to fully comprehend how insulin pump market operate. As a result, we will go through the many types of insulin pumps as well as each component portion in this post. The insulin pump market is a somewhat compact electronic gadget (around the size of a Samsung galaxy s5) that may be simply fastened to a belt or other items of clothing and it is connected to your body by way of an infusion set, which is essentially a skinny tube through which your insulin is administered.

Impact of Covid on the Insulin Pump Market

A recently identified viral condition called COVID-19, which is brought on by the SARS-CoV-2 virus, has been observed to damage not only the respiratory system but also the heart, kidney, digestive system, blood, and brain system. Patients with diabetes are more susceptible to infectious agents due to their weakened immune systems and inability to protect themselves from harmful germs.

Furthermore, people with diabetes often have poor glycaemic control, which increases their risk of contracting a virus. Most diabetic individuals are reported to be obese, and obesity itself increases the chance of COVID-19 infection because of decreased metabolism and immune system weakness.

Angiotensin-converting enzyme inhibitors are used to treat diabetes, and it has been found that coronavirus binds to target cells via this enzyme, which is expressed in the blood vessels and lungs. Diabetes individuals have higher levels of the ACE2 enzyme, which raises their risk of developing COVID-19.

The Prevalence of Diabetes Boosts the Demand

One of the drivers of the market’s expansion is the rise in diabetes cases brought on by age, obesity, and bad lifestyle choices. Diabetes is mostly brought on by obesity, which also contributes to the rise of ocular problems linked to diabetes. Around 22.9 million people worldwide were estimated to have diabetes in 2017, compared to 476.0 million for the prevalence, 1.37 million deaths from the disease, and 1.37 million disability-adjusted life years (DALYs) linked to diabetes.

According to the WHO, 650 million persons were classified as obese in 2017 out of approximately 1.9 billion who were overweight. Obesity and being overweight are risk factors for type II diabetes, which is becoming more common.

For instance, according to Diabetes Canada, one in three Canadians had diabetes or prediabetes in 2019. Less than half of Canadians can identify half of the early diabetes warning signs. Additionally, just 33% of Canadians are aware that diabetes can cause strokes as a side effect. 14.5% of the population in Japan had diabetes in 2019 (defined as having an A1C of 6.5 percent or higher or receiving treatment for the ailment), with 55.6% of those individuals taking medication, according to the Japanese Ministry of Health, Labor, and Welfare (including insulin injections). In 2019, there were 12.7% more persons with diabetes.

Major competitors in the global market for insulin pump market are employing a variety of strategies to compete successfully. To deliver technology-driven products, they are increasing their investments in research and development operations. Additionally, partnerships, mergers, acquisitions, and the adoption of cutting-edge technology are some other tactics used by the major players in the global insulin pump market.

Technological Development & Product Approval Featuring Market in Coming Years

The advancement of technology in medical devices used to treat diabetes, such as continuous glucose monitoring (CGM) and insulin pump market has increased and the competition to produce the most advanced products will increase demand for CGM and insulin pump market, creating possibilities for market competitors shortly. For instance, in January 2019, a research team at KTH Royal Institute of Technology in Stockholm, Sweden, developed and launched a glucose monitoring device that is 50 times smaller than the needles used in current continuous glucose monitoring (CGM) systems.

The new microneedle patch is designed to test glucose directly in the skin, which is nearly painless because there are no pain-detecting nerve receptors there.

Due to the increasing use of diabetes pumps in emerging and developing countries, market participants must focus on the R&D of technologically improved goods and the introduction of new products.

The transmitters segment is estimated to be valued at US$ more than 180.25 Mn in 2022 and is expected to reach more than US$ 1,117.38 Mn by 2030 at a CAGR of 21.7%. Transmitters are an integral part of continuous glucose monitoring devices. A transmitter works along with a receiver to collect readings from the sensor and displays the results on a continuous glucose monitor. The transmitter receives a tiny electric current from the sensor and sends out a short-range radio signal. It is flat, small, and compact as well as waterproof. A transmitter has a battery, which is either permanent or can be replaced periodically.

The signal from the transmitter is received by a battery-powered handheld receiver that displays glucose monitoring results.

The type 1 diabetes segment is estimated to be valued at US$ 136.41 Mn in 2022 and is expected to reach US$ 539.56 Mn by 2030, growing at a CAGR of 18.8% during the forecast period. Type 1 diabetes is caused by an autoimmune reaction, in which the body’s defined system attacks the insulin-producing beta cells in the pancreas. As a result, the body can no longer produce the insulin it needs and most patients with type 1 diabetes use insulin injections daily and adjust insulin administration based on pre-prandial and postprandial self-monitored blood glucose (SMBG) values.

The type 2 diabetes segment is estimated to be valued at US$ 1,073.97 Mn in 2022 and is expected to reach US$ 5,267.31 Mn by 2030, growing at a CAGR of 22.0%.

North America Carries the Largest Revenue

Due to the presence of significant players in the insulin pump market, North America dominated the market and held the greatest revenue share of around 46.7% in 2022. Additionally, it is anticipated that the market in the region would be driven by the rising incidence of obesity, high treatment costs, technological advancements, and new releases.

Due to a rise in the number of elderly people, who are more susceptible to diabetes, Europe is also anticipated to gain a sizable market share throughout the projection period. Additionally, the region’s increased demand for insulin pumps is being fuelled by advancements in its healthcare system and the use of cutting-edge medical items.

Competitive Landscape

The global insulin pump market is consolidated with a few major market players operating worldwide. The key players of the insulin pump market – Tandem Diabetes Care, Inc., Medtronic plc, Insulet Corporation, and Roche Holding AG – are also profiled with their financial information and respective business strategies.

Projections and Trends: Navigating the Future Landscape

Projected Valuation Milestones:

The projection of reaching US$ 15.28 billion by 2032 is not merely a numerical estimate but a testament to the market’s significance in revolutionizing diabetes management. As the demand for technologically advanced solutions continues to soar, the financial milestones become more tangible and achievable.

Integration Trends: Shaping the Future of Diabetes Care

In the ever-evolving landscape of the insulin pump market, integration trends play a pivotal role. Seamless integration with CGM systems, enhanced connectivity features, and user-centric designs shape the future of diabetes care. As these trends gain prominence, the market solidifies its position as a frontrunner in facilitating a paradigm shift in how diabetes is managed.

Conclusion: Pioneering Diabetes Care Innovation

In conclusion, the projected growth of the insulin pump market signifies a pioneering era in diabetes care. Fueled by technological advancements and the unwavering focus of industry players, the market becomes a driving force in transforming the landscape of diabetes management. As we navigate the future, the insulin pump market stands tall as a symbol of innovation, offering hope and improved quality of life for those managing diabetes.

January 2, 2024